focus -WSS

focus

author：leisure time 2025-08-11 09:47:37 - browse：297

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： TB outbreak tied to bone grafts underscores testing shortcomings

focus

WSS

Listen: Your guide to Wegovy's blockbuster heart study

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Clinical trials giant ICON acquires HumanFirst

House looks to weaken Medicare negotiation

Novo acquires Inversago for up to $1 billion

FDA does about

focus

focus

leisure time

Trump demands the U.S. pay no more for drugs than other countries … again

Change Healthcare cyberattack outage could last weeks

In age of alternative facts, a scholarly course on calling out crap

An innovative path out of biotech’s “valley of death”

Wildfire smoke exposes gaps in outdoor worker protections

Covid's long

Virginia high school admissions case could be legal follow

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Malaria cases in Florida and Texas: Here’s what you need to know

Maui funeral service workers on devastation of fires: 'I'm in shock'

hotspot

Target recalls 2.2 million additional candles due to laceration, burn hazards

Maui funeral service workers on devastation of fires: 'I'm in shock'

Listen: Your guide to Wegovy's blockbuster heart study

An innovative path out of biotech’s “valley of death”

TB outbreak tied to bone grafts underscores testing shortcomings

Timeline: Special counsel's investigation into Trump's handling of classified documents

entertainment

focus

focus

entertainment